Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) induce high rates of reversion to normoglycemia in individuals with prediabetes, but these benefits are largely lost upon discontinuation of the therapy.
GLP-1 medications like semaglutide are highly effective at reversing prediabetes, with nearly all users returning to normal blood sugar levels while taking the drug. However, stopping the medication usually leads to weight regain and the return of prediabetes. Discuss with your doctor whether this is a short-term reset or a long-term management strategy for you.
discontinuation of semaglutide led to regaining two thirds of the initial weight loss and redevelopment of prediabetes... Weight regain occurred after discontinuing tirzepatide, and initial improvements in cardiometabolic risk factors—including FPG and HbA1c—also reversed with weight regain.
Why this rating
Based on randomized controlled trials (STEP 1, etc.) showing high efficacy and clear discontinuation effects.
Source
Reframing prediabetes: A call for better risk stratification and intervention
Sun H. Kim · Journal of Internal Medicine · 2024
DOI 10.1111/joim.13786
More from this paper
- Meeting multiple glycemic criteria (IFG, IGT, and/or elevated HbA1c) for prediabetes significantly increases the risk of progressing to type 2 diabetes compared to meeting only one criterion.Good
- Lifestyle interventions (diet and exercise) reduce the incidence of type 2 diabetes in individuals with prediabetes, but the benefit is primarily established for those with Impaired Glucose Tolerance (IGT) and may not apply to those with isolated Impaired Fasting Glucose (IFG).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →